Clinical trial
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
NCT00289562 · BioCryst Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00289562 |
|---|---|
| Title | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia |
| Official title | A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients With B-Cell Acute Lymphoblastic Leukemia With an Option of Extended Use of Forodesine Hydrochloride |
| Lead sponsor | BioCryst Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Acute Lymphoblastic Leukemia |
| Intervention type | Drug |
| Interventions | forodesine hydrochloride (BCX-1777) |
| Enrollment | 20 |
| Start date | Sep 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Feb 10, 2006 |
| Last update posted | Jan 20, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: